COVID Supplement

University Of Chicago, Chicago IL

Investigators

Abstract

The contractor had previously discovered inhibitors of the NFkB-pathway which inhibited systemic inflammation when delivered together with a TLR-agonist, while improving antibody responses induced by vaccines formulated with this combination adjuvant. They will apply this finding to subunit SARS-CoV2 vaccines and test the immunogenicity and efficacy of such novel vaccine formulations.